2020-2027 Analysis and Review Manidipine Hydrochloride Market

Manidipine Hydrochloride Market

Manidipine Hydrochloride Market By Clinical Application (Moderate Hypertension and Renal Protection in Type 2 Diabetes), By Treatment Regimen (Monotherapy and Combination Therapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

16-05-2020 REP-HC-5087 40 Tables 110 pages Format

The manidipine hydrochloride market was valued at USD 393.5 Mn by 2019. A constant rise in the consumption of alcohol, tobacco, unhealthy diet, stress giving rise to mild to moderate hypertension in the young adult population worldwide. A significant increase in the renal complication in elderly patients having preexisting comorbidities of type 2 diabetes and hypertension drives the manidipine hydrochloride market growth.

Manidipine Hydrochloride Market

Manidipine hydrochloride is a dihydropyridine that is classified as a calcium channel blocker that is used as an antihypertensive agent that produces vasodilation of the vascular smooth muscles to lower the peripheral blood pressure. At clinically relevant dosage it does not produce any effect on the central nervous system and heart. 

The major segments related to the manidipine hydrochloride market are: 

By Clinical Application (2017–2027; US$ Mn)

Moderate Hypertension

Renal Protection in Type 2 Diabetes

By Treatment Regimen (2017–2027; US$ Mn)

Monotherapy

Combination Therapy

Geography Segment (2017–2027; US$ Mn)

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global manidipine hydrochloride market
  • The overall segmentation of the manidipine hydrochloride market, by clinical application, treatment regimen, and geography is minutely studied. Moderate hypertension and monotherapy are dominating the clinical application and treatment regimen segments respectively
  • Significant increase in the number of young adult population suffering with mild to moderate hypertension throughout the globe
  • A constant rise in the number of people suffering from renal complication due to preexisting comorbidities such as hypertension and type 2 diabetes worldwide

Report gist?

  • The study of the global manidipine hydrochloride market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and treatment regimen and categorization of the same at geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of manidipine hydrochloride on account of the significant increase in the number of young adult population suffering with moderate hypertension
  • The report will benefit cardiologist engaged in the management of renal complications in patients suffering from existing comorbidities such as hypertension and type 2 diabetes
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to manidipine hydrochloride market
  • Banking agencies, healthcare foundation & trust agencies, scientists, angel investors, regulatory agencies, healthcare professionals and health economists looking for insights into the market to determine future strategies

Segment Analysis

Moderate hypertension is presently reigning the clinical application segment for the manidipine hydrochloride market. As per the research citings provided by the World Health Organization (WHO), each year approximately 17 million people die worldwide due to cardiovascular complications. Furthermore, it is estimated that 50% of the patients suffering from moderate hypertension are subjected to suffer from myocardial infarction or stroke if proper treatment regimen is not followed. Renal protection in type 2 diabetes will be the fastest-growing application segment during the forecast period. Renal impairment is a common clinical manifestation in type 2 diabetic patients with hypertension (serum creatinine levels ≤ 3 mg/dl) who are above 50 years of age. Clinical trials have shown positive evidences that manidipine has lower urinary albumin excretion rate and has a lower risk of ankle edema in comparison to other calcium channel blockers. 

Currently monotherapy is leading the treatment regimen segment for the manidipine hydrochloride market. Manidipine 10-20mg once daily is prescribed for patients suffering from moderate hypertension. Combination therapy is gaining tremendous traction in the last 2 decades owing to a significant increase in the number of patients suffering from renal complication with preexisting comorbidities if type 2 diabetes and hypertension. Delapril 30mg/manidipine 10mg is prescribed for its ability to manage renal complications in type diabetic patients with hypertension. 

Europe is currently spearheading the regional segment for the manidipine hydrochloride market. Rising prevalence of lifestyle disorders such as cardiovascular disease, diabetes, etc. primarily drives the manidipine hydrochloride market growth in the region. As per the latest research citings provided by the European Heart Network (EHN), approximately 37% of the deaths recorded in the European Union is associated with cardiovascular complication. Domicile of major players such as Chiesi Farmaceutici s.p.a., Takeda Italia SpA, Bennett SA, Mylan Pharmaceutical Industries Ltd., etc. further propel the market growth in the region. The USFDA has not recommended the use of manidipine hydrochloride in North America. It is anticipated that in the near future Asia Pacific will be registering remarkable market growth on account of rising prevalence of geriatric population suffering from renal impairment and preexisting hypertension. Effective implementation of treatment guidelines pertaining to hypertension management further accentuates the manidipine hydrochloride market growth in the Asia Pacific.

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.